Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study

Veysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı · 2026

Read Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study by Veysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13479832.txt.

Description

Veysel Baran Tomar and coauthors published a 2026 one-time study of silent ketone buildup in clinic patients with diabetic kidney disease on SGLT-2 blocker drugs. These drugs are now standard for this group, yet they nudge the body toward making ketones. Full ketone acid buildup in the blood is a known danger, while mild symptom-free ketone rise had never been carefully measured.

The study took in 211 adults in a row on empagliflozin or dapagliflozin. A finger-prick ketone meter read the main ketone body after a set fast. Math models then showed which traits on their own pointed to a high reading. Knowing who quietly runs ketones could help doctors decide who needs home checks or sick-day drug pauses to dodge a crisis.

Catalog record

CREATORVeysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34485
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13479832

Browse the full library · About the Tower of Babel